Reforming Payment for Clinician-Administered Drugs — Most-Favored-Nation Pricing in Medicare Part B

The Trump administration’s proposed GLOBE model would align Medicare Part B payments for clinician-administered drugs with international pricing benchmarks, with CMS estimating $11.9 billion in Medicare savings and $6.2 billion in reduced beneficiary cost-sharing over seven years. The model would be strengthened by incorporating clinical benefit into rebate determinations, replacing the lowest-available-list-price benchmark with average international prices to reduce manufacturer gaming, and expanding the program nationwide if evidence of improved health outcomes emerges.